|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 116, 763-769, Copyright © 1998 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
NOTE: Fulltext is available only in pdf format
U Sayeed-Shah, MJ Mann, J Martin, S Grachev, S Reimold, R Laurence, V Dzau and LH Cohn
INTRODUCTION: Transmyocardial laser revascularization is believed to induce
an angiogenic response within ischemic myocardium. We evaluated transgene
expression in the setting of transmyocardial laser revascularization and
hypothesized that intramyocardial injection of plasmid DNA encoding the
gene for vascular endothelial growth factor could enhance the
revascularization achieved by transmyocardial laser revascularization,
resulting in improved cardiac function. METHODS: Ten Yorkshire pigs had
carbon dioxide-transmyocardial laser revascularization or acupuncture sites
with injections of an expression plasmid encoding the gene for
beta-galactosidase with or without HVJ- liposomes. Three days after
transduction, transgene expression was determined by enzyme-linked
immunosorbent assay. Six weeks after placement of a constrictor on the left
circumflex artery, 29 pigs were randomized to ischemic controls (n = 5),
transmyocardial laser revascularization (n = 4), transmyocardial laser
revascularization with expression plasmid beta-galactosidase injections (n
= 5), expression plasmid-vascular endothelial growth factor injections (n =
4), or transmyocardial laser revascularization with expression plasmid-
vascular endothelial growth factor (n = 5) and harvested 6 weeks after
therapy. Six transmyocardial laser revascularization pigs had either
expression plasmid beta-galactosidase or expression plasmid-vascular
endothelial growth factor injections and were harvested at 2 weeks. Normal
pigs (n = 5) were included for comparison. Left ventricular free wall
motion was assessed by a cardiologist in a blinded manner. RESULTS:
Transgene expression did not vary significantly with or without
HVJ-liposomes in transfected transmyocardial laser revascularization
myocardium. However, expression was detected in 56 of 60 (93%)
transmyocardial laser revascularization-transfected sites, but in only 10
of 20 (50%) non-transmyocardial laser revascularization sites (P <
.001). All (5 of 5 hearts) of the transmyocardial laser
revascularization-vascular endothelial growth factor treated hearts
displayed no evidence of wall motion abnormalities. Only these hearts had a
statistically significantly different rate of wall motion abnormality
compared with ischemic controls (P = .004). CONCLUSION: Transfection
efficiency was improved with the use of transmyocardial laser
revascularization. Wall motion abnormalities were completely reversed
within 6 weeks after transmyocardial laser revascularization with the
direct injection of an expression plasmid encoding vascular endothelial
growth factor.
ARTICLES
Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization
Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
This article has been cited by other articles:
![]() |
K. A. Horvath and Y. Zhou Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow Card. Surg. Adult, January 1, 2008; 3(2008): 733 - 752. [Full Text] |
||||
![]() |
T. Attmann, C. Heilmann, M. Siepe, J. Martin, F. Jentzmik, P. von Samson, F. Beyersdorf, and G. Lutter Transgenic and transmural revascularization: regional myocardial tissue pressure during chronic ischemia Interactive CardioVascular and Thoracic Surgery, March 1, 2004; 3(1): 138 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Hughes, M. J. Post, M. Simons, and B. H. Annex Translational Physiology: Porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis J Appl Physiol, May 1, 2003; 94(5): 1689 - 1701. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A.U. Heilmann, T. Attmann, P. von Samson, H. Gobel, D. Marme, F. Beyersdorf, and G. Lutter Transmyocardial laser revascularization combined with vascular endothelial growth factor121 (VEGF121) gene therapy for chronic myocardial ischemia - do the effects really add up? Eur. J. Cardiothorac. Surg., January 1, 2003; 23(1): 74 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ruel, R. A. Kelly, and F. W. Sellke Therapeutic Angiogenesis, Transmyocardial Laser Revascularization, and Cell Therapy Card. Surg. Adult, January 1, 2003; 2(2003): 715 - 750. [Full Text] |
||||
![]() |
G. Lutter, T. Attmann, C. Heilmann, P. von Samson, B. von Specht, and F. Beyersdorf The combined use of transmyocardial laser revascularization (TMLR) and fibroblastic growth factor (FGF-2) enhances perfusion and regional contractility in chronically ischemic porcine hearts Eur. J. Cardiothorac. Surg., November 1, 2002; 22(5): 753 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Huikeshoven, J. F. Beek, J. A.P. van der Sloot, R. Tukkie, J. van der Meulen, and M. J.C. van Gemert 35 years of experimental research in transmyocardial revascularization: what have we learned? Ann. Thorac. Surg., September 1, 2002; 74(3): 956 - 970. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Meerkin, M. Pellerin, H. T. Aretz, P. Paiement, S. L. Houser, and R. Bonan Transmyocardial coil implants: a novel approach to transmyocardial revascularization Ann. Thorac. Surg., August 1, 2002; 74(2): 488 - 492. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Tabibiazar and S.G Rockson Angiogenesis and the ischaemic heart Eur. Heart J., June 1, 2001; 22(11): 903 - 918. [PDF] |
||||
![]() |
H.K. Hammond and M.D. McKirnan Angiogenic gene therapy for heart disease: a review of animal studies and clinical trials Cardiovasc Res, February 16, 2001; 49(3): 561 - 567. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fuchs and R. Kornowski Transepicardial or transendocardial injury: controversies regarding angiogenic potential and mechanism of action Cardiovasc Res, February 16, 2001; 49(3): 582 - 587. [Full Text] [PDF] |
||||
![]() |
V. J. Dzau, M. J. Mann, A. Ehsan, and D. P. Griese Gene therapy and genomic strategies for cardiovascular surgery: The emerging field of surgiomics J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0206 - 216. [Full Text] [PDF] |
||||
![]() |
L. Y. Lee, M. F. O'Hara, E. B. Finnin, R. Hachamovitch, M. Szulc, P. D. Kligfield, P. M. Okin, O. W. Isom, and T. K. Rosengart Transmyocardial laser revascularization with excimer laser: clinical results at 1 year Ann. Thorac. Surg., August 1, 2000; 70(2): 498 - 503. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Martin, U. Sayeed-Shah, J. G. Byrne, M. H.D. Danton, K. Q. Flores, R. G. Laurence, and L. H. Cohn Excimer versus carbon dioxide transmyocardial laser revascularization: effects on regional left ventricular function and perfusion Ann. Thorac. Surg., June 1, 2000; 69(6): 1811 - 1816. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Horvath, E. Chiu, D. C. Maun, J. W. Lomasney, R. Greene, W. H. Pearce, and D. A. Fullerton Up-regulation of vascular endothelial growth factor mrna and angiogenesis after transmyocardial laser revascularization Ann. Thorac. Surg., September 1, 1999; 68(3): 825 - 829. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |